Pharmacia & Upjohn Company

Zoetis Services LLC

Todd P Foster

Michael John Hageman

Laibin Luo

James F Caputo

William M Moseley

Michael John Hawley

Sumitra Rajagopalan

Derek James Sheehan

Nicholas Finn Cunningham

Karen Barsuhn

John Mark Heimlich

Jeffrey Ellis Price

Changquan Sun

Fusen Han

David L Kiefer

Tom Thamann

Vijaya Bharti Joshi

Christina Lee Brown

Alexandre Therrien

Oscar Suarez

The invention describes a ready-to-use injectable cephalosporin composition with reasonable viscosity, resuspendability, and syringeability attributes for injection as an antibiotic for animals.

Ready-to-use injectable formulations

The present disclosure relates generally to sol-gel polymer composites that comprise chitosan, a hydrophilic polymer, a polysiloxane, and a gelation agent in a suitable medium. Advantageously, the sol-gel polymer composite can form a durable seal or strong solid in response to one or more physiological stimulus. The disclosure further relates to medical and veterinary uses of the composite, particularly, methods and delivery systems for reducing or preventing the incidence of a mammary disorder in a dairy animal. More particularly, the disclosure includes methods and sol-gel polymer composite compositions for creating a physical barrier on the teat surface or in the teat canal or cistern of a non-human animal for prophylactic treatment of mammary disorders such as mastitis wherein the sol-gel polymer creates a seal in response to one or more physiological stimulus.

Veterinary compositions for use in treating mastitis, and associated methods

The invention describes a long-acting injectable veterinary composition comprising a spirocyclic isoxazoline, at least one biopolymer, and optionally, at least one veterinary acceptable-carrier, -solvent, -excipient, or any mixture thereof. The invention also includes a method of treating an animal with a parasitic infestation by administering the biopolymeric composition to the animal in need thereof, and a process for preparing the biopolymeric composition.

Long-acting spiro-isoxazoline formulations

The present invention relates to polymorphs of the 3-pyrrole substituted 2-indolinone compound 5-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide.

Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Prolonged parenteral release into the circulatory system of a cow of a bioactive growth hormone releasing factor at desirably effective levels can be achieved using novel compositions in which the growth hormone releasing factor is present in an aqueous liquid at a dose of at least about 50 mg and at a concentration of at least about 20 mg/ml. Preferably, the growth hormone releasing factor is present in an aqueous liquid at a dose of about 200 mg and at a concentration of about 180 mg/ml. The aqueous bovine growth hormone releasing factor formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than seven (7) days.

Aqueous prolonged release formulation

Prolonged parenteral release into the circulatory system of a cow of a bioactive growth hormone releasing factor at desirably effective levels can be achieved using novel compositions in which the growth hormone releasing factor is present in an aqueous liquid at a dose of at least about 50 mg and at a concentration of at least about 20 mg/ml. Preferably, the growth hormone releasing factor is present in an aqueous liquid at a dose of about 200 mg and at a concentration of about 180 mg/ml. The aqueous bovine somatotropin formulation provides for the sustained release of bovine somatotropin into the circulatory system of the animal for greater than seven (7) days.

The present invention provides an oil composition for parenteral administration comprising a dihydropolyprenol of formula I and a pharmaceutically acceptable oil ##STR1## wherein n is an integer of 5 to 7.

Oil composition of dihydropolyprenols

The present invention provides for the inclusion of small amounts of water in oil suspensions of active drugs, such as ceftiofur hydrochloride of formula I. The resulting suspensions have improved resuspendability. Improved resuspendability results in an improved product because less shaking of the suspension is required before dosing. ##STR1##

Growing community of inventors

Kalamazoo, MI, United States of America

Todd P Foster